The Management
Of Research And Development
And The Relevance
Of Financial Accounting

Paul E. Nix, Montana State University – Bozeman, E-mail: pnix@montana.edu
Roberto de Magalhaes, Texas A&M University, E-mail: roberto@cob.tamucc.edu
William Wilcox, Bradley University -- Illinois, E-mail: wwilcox@bradley.edu

Abstract

This study investigates alternatives to current financial accounting treatment of research and development expenditures in United States public corporations. A questionnaire survey was sent to members of the Financial Directors Network of the Industrial Research Institute of America, representing over forty percent of private research and development in the United States. Background research and the survey indicate that if the financial reporting of research and development is modified, research and development will increase and a shift from short-term to long-term projects will occur; and finally United States public corporations will more effectively compete in the international markets.

Synopsis and Introduction

The outlook for R&D in 2001 continues to be strong. In 1998, U.S. R&D grew by 6.5% after adjusting for inflation. However, “Of the top 20 corporations investing in 1998 R&D, only eight will be U.S. firms. It was not long ago that U.S. firms dominated the top 20 list with 15 of the largest of the R&D spenders” (Wolff, 2000). The Council on Competitiveness report states “…the United States is not laying the foundation for its long-term prosperity…based upon R&D statistics” (Council on Competitiveness, 1999). “The trend away from basic research toward more product development and technical service, first detected in the late 1980’s…continues” (Wolff, 1994). Numerous studies with controversial results have investigated the possible effects of the financial accounting treatment of U.S. R&D expenditures on R&D spending (Dukes, 1980; Elliott, 1984; Ball, 1980; Bierman and Dukes, 1975; Braitwaite, 1967). The forces that influence R&D spending in addition to financial accounting are many and varied including management, internal cash flow, capital markets, government policy and perhaps most important available research projects. Financial accounting may be becoming less relevant to external users and the capitalization of R&D may be useful (Lev and Zarowin, 1999). In an information based economy, R&D should be even more important; however, research discloses in a random sample of the Fortune 500 companies that R&D as a percent of sales has remained constant from 1986 through 1998 (Compustat Data, 1999). Why has R&D not increased in importance to sales? The effect of the financial accounting of R&D expenditures on R&D spending may be part of the answer.

Historically, expensing versus capitalizing research and development (R&D) expenditures has long been an important and controversial topic with few popular accounting treatments (Lev and Zarowin, 1999; Nix, 1992; Gellein and Newman, 1973; Wolf, 1989; Marshal, 1980; Newman, 1988; Munson, 1987; Nixon and Lonie, 1990; Guerard, 1987; Selto and Clouse, 1986; Horwitz and Koldony, 1980; Wolfson, 1980; Higgins, 1954). The mandated accounting treatment, SFAS No. 2, 1974, which requires public corporations to expense R&D expendi-
tures in the period incurred, provides a strong incentive to decrease R&D, because expensed R&D has an immediate adverse impact on reported profits. International business firms do not suffer under this impact which may effect the relevancy of financial earnings (Barth and Clinch, 1998; Carnegie and Turner, 1987). Imagine expensing a plant during construction, such as the multi-million dollar Utah chip production plant which never opened in 1999 or 2000. The same effect may occur when intangible assets arising from research costs are expensed in the year they are incurred. The mandated expense treatment provides an incentive to spend a disproportionate share of R&D on projects that have a short-term rather than long-term return. Researching a new product frequently requires a 5 to 10 year investment (Biggadike, 1979). Traditionally the product life cycle has been even longer. Thus research planning influenced by quarterly or annual reported earnings may adversely affect both individual companies as well as our national economy. When a capital asset such as R&D is expensed in the year incurred, reported income is distorted due to a lack of matching of expenditures with related revenue generation (Thomas, 1969). Prior to 1974, financial reporting of R&D expenditures ran the gauntlet between full capitalization in the year incurred versus full expensing in the year incurred (SFAS No. 2, 1974). The impact of tax policy on financial reporting no doubt influenced the passage and acceptance of SFAS No. 2. The use of a contra stockholders’ equity account in which all R&D expenditures would be placed when incurred and then later amortized is a possible compromise solution; immediate write off for tax purposes need not be affected (Raby, 1967; Tax Foundation, 1990). At the end of each year a fixed percent (such as 20%) of what is remaining in the equity account from prior years’ expenditures would be charged to R&D expense for the current year. With this proposed contra stockholder account method, during periods of increasing R&D expenditures, current R&D expenses would be less than under the required expense-as-incurred method. Thus, under the proposal, the current R&D expenditures would be expensed over their future revenue-producing period; but, during periods of decreasing R&D expenditures, current R&D expenses would be greater under the proposed method than in current practice. Again, R&D expenditures are more closely matched to their revenue-producing period. When there is no change in the total R&D expenditures from year to year, current R&D expenses would be the same under the proposal and the required expense-as-incurred method. Thus, R&D expenditures would be more closely matched to R&D revenue generated under the proposed contra stockholder equity account method under all budgeting situations. The proposal also encourages a shift from short- to long-term R&D under all three situations. (See Illustration of “Contra Stockholder Equity” Approach)

The use of a contra stockholders’ equity approach is already required and used in accounting for the unrealized loss on long-term marketable securities, the translation gains and losses on foreign currency amounts, the net loss not recognized as pension expense and treasury stock transactions (SFAS No. 12, 1975; SFAS No. 52, 1981; SFAS No. 87, 1988).

In the current study members from the Financial Directors Network of the Industrial Research Institute, representing over 40 percent of the industrial R&D in the U.S., responded to a questionnaire survey. Greater than 50% of those receiving the questionnaire replied in a usable format. These respondents represent corporations, which account for over 20 percent of the corporate R&D spending in the U.S. The average annual R&D expenditures of these companies are 65% of average annual profits. When R&D expenditures are 65% of profits, it is easy to picture how, under current practice, R&D expenditures may be cut back to boost profit during a profit squeeze.

Results of Questionnaire

Questions asked referred to the use of such a contra stockholders’ equity account and to what was the most appropriate financial disclosure of R&D expenditures in general. When asked the following question, “After enactment of this proposal, the current year’s expenses would normally be unaffected by the current year’s R&D expenditures. When current profits are unsatisfactory to higher management, in general, what effect (if any) would the proposed method have on current year R&D expenditures relative to the now required expense as incurred practice?” 48% indicated that they would increase their current year’s R&D, 12% indicated a decrease, and 40% indicated no change. These results indicate that our present “expense as incurred rule” may well inhibit total R&D expenditures in the periods they are most badly needed. Also, some companies would be affected while many others would not.

Illustration of “Contra Stockholder Equity” Approach
Accounting information about an unidentified company as of 12/31/99
(amounts in millions)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$600</td>
<td>$590</td>
<td>$580</td>
<td>$560</td>
<td>$530</td>
<td>$480</td>
</tr>
</tbody>
</table>

Tax rate all years: 37%

Pre-tax and pre-R&D amortization income for 1999: $1,000

Accounting entries required on 12/31/99, if the “contra stockholders’ equity approach to the accounting treatment of R&D expenditures were implemented in an unidentified company as of 1/1/99 (amounts in millions):

1. Contra-stockholders Equity
   Cash $600
   (R&D 1999 expenditures)

2. R&D Amortization Expense
   Contra-stockholders’ equity account $548
   (to recognize 1999 R&D amortization expense)
   $590 + $580 + $560 + $530 + $480 x 20% = $548

3. Income Tax Expense*
   Income Taxes Payable* $148
   Deferred Tax Liability* $19
   (to recognize tax expense, taxes payable and deferred taxes; a pretax income before R&D amortization expense is assumed to be $1,000)

*Computations:

For financial statement purposes

<table>
<thead>
<tr>
<th>Income before R&amp;D expense and Taxes are deducted:</th>
<th>$1,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less R&amp;D amortization expense</td>
<td>548</td>
</tr>
<tr>
<td>Taxable income:</td>
<td>542</td>
</tr>
<tr>
<td>Tax rate:</td>
<td>37%</td>
</tr>
<tr>
<td>Taxes payable:</td>
<td>$167</td>
</tr>
</tbody>
</table>

For computing taxes payable

<table>
<thead>
<tr>
<th>Income before R&amp;D expense and Taxes are deducted:</th>
<th>$1,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less R&amp;D amortization expense</td>
<td>548</td>
</tr>
<tr>
<td>Taxable income:</td>
<td>542</td>
</tr>
<tr>
<td>Tax rate:</td>
<td>37%</td>
</tr>
<tr>
<td>Taxes payable:</td>
<td>$148</td>
</tr>
</tbody>
</table>

Deferred tax liability: $167 – $148 = $19

When asked the following question, “After enactment of this proposal, what effect (if any) will there be on the amount of annual R&D expenditures relative to the amount your firm would have spent each year under the now required expense as incurred practice?” 32% answered that R&D expenditures would be increased. The remaining 68% replied that there would be no effect. Once again, we are reminded that the proposed method may have a significant impact on increasing R&D expenditures.

When asked the following question, “After enactment of this proposal, what effect (if any) relative to present practice will there be in the amount of long-term R&D expenditures compared to short-term R&D expenditures? Nearly one-half (44%) of the respondents indicated that there would be an increase in long-term compared to
short-term R&D expenditures under the proposed method, while 56% indicated there would be no effect. United States industry has, for many years, been frequently criticized for emphasizing short-term returns at the expense of overall long-term benefit. It is significant that simply by changing the required method of financial reporting, nearly one-half of the respondents would spend less of their total R&D budget on short-term projects and more on long-term. It is apparent that required financial reporting is influencing corporate financial management to make decisions that conflict with sound R&D management and the long-term benefit of the company.

A pressing problem in R&D budgeting in many companies is annual fluctuation of R&D expenditures. This is certainly due, in part, to keeping short-term financial reported profits stable or positive. With this in mind, respondents were asked the following question: “After enactment of this proposal, what effect (if any) relative to present practice will there be in the annual fluctuations (if any) of R&D expenditures?” Over one-third (33%) of the respondents replied that there would be a decrease in annual fluctuations, 8% indicated an increase, while the remaining 56% believed there would be no effect. We are not suggesting there would not be annual fluctuations in R&D expenditures but rather that fluctuations should not be a result of financial reporting requirements which may pressure managers to decrease R&D at times when it is most badly needed.

Finally, answering the last questions, “Do you feel this contra stockholders’ equity method of accounting for R&D may allow U.S. companies to compete more effectively in the international market?” 42% of the respondents answered yes, 54% no and 4% not sure. Presumably, the respondents answering “yes” did so because they felt that the proposed method would provide an incentive for more to be spent on R&D or a shift in R&D to longer term projects or both.

A separate part of the questionnaire listed four proposed methods of reporting research and development expenditures in published financial statements. After reading the four methods, respondents were asked to indicate on a scale, from 1-least appropriate, to 7-most appropriate how appropriate each method would be for their firm. The methods scored, respectively, as follows: the expense-as-incurred method in practice, an average of 5.6; the proposed contra stockholders’ equity method, and average of 4; a capitalization and fixed write-off method, and average of 2.5; and a choice of either capitalization (shown as an asset) or charge to income as incurred, depending on estimates of future productiveness, an average of 2.6. It is noteworthy that the proposed contra stockholder method scored almost as high as the expense-as-incurred method use in practice. This is particularly so because the above numbers represent the averages for all respondents. Figure 1. shows relative appropriateness of each of four possible methods of accounting for research and development costs as published financial statements.
Conclusions

Results from this study tentatively indicate that if the contra stockholders’ equity method were used for the financial reporting of R&D expenditures, a larger total dollar amount of R&D would be spent, a shift in total R&D toward longer projects would occur, U.S. companies would compete more effectively in the international market, and the relevancy of financial accounting earnings would be improved. Thus, the expense-as-incurred method of accounting for R&D is impeding sound corporate R&D decision making. However, the respondents still selected that the most appropriate method of accounting for R&D is the expense-as-incurred method. They indicated, in writing, a concern that a less favorable R&D tax policy could be the result of any change, but tax policy need not be changed.

Suggestions for Future Research

Since R&D Expenditures are such an important component in business enterprise continued research into possible capitalization and future write-off of R&D should occur. This additional research should be undertaken regarding the financial reporting of R & D expenditures, R & D tax policy, and the impact of the proposed contra-stockholders’ equity method on company size within all industries.

References